Keratinocytes: innate immune cells in atopic dermatitis
- Panjit Chieosilapatham,
- Chanisa Kiatsurayanon,
- Yoshie Umehara,
- Juan Valentin Trujillo Paez,
- Ge Peng,
- Hainan Yue,
- Le Thanh Hai Nguyen,
- Francois Niyonsaba
Yoshie Umehara
Juntendo University School of Medicine Graduate School of Medicine
Author ProfileJuan Valentin Trujillo Paez
Juntendo University School of Medicine Graduate School of Medicine
Author ProfileGe Peng
Juntendo University School of Medicine Graduate School of Medicine
Author ProfileHainan Yue
Juntendo University School of Medicine Graduate School of Medicine
Author ProfileLe Thanh Hai Nguyen
Juntendo University School of Medicine Graduate School of Medicine
Author ProfileFrancois Niyonsaba
Juntendo University Graduate School of Medicine
Author ProfileAbstract
The skin is a unique immune organ that constitutes a complex network of
physical, chemical, and microbiological barriers against external
insults. Keratinocytes are the most abundant cell type in the epidermis.
These cells form the physical skin barrier and represent the first line
of the host defense system by sensing pathogens via innate immune
receptors, initiating antimicrobial responses and producing various
cytokines, chemokines and antimicrobial peptides, which are important
events in immunity. A damaged epidermal barrier in atopic dermatitis
allows the penetration of potential allergens and pathogens to activate
keratinocytes. Among the dysregulation of immune responses in atopic
dermatitis, activated keratinocytes play a role in several biological
processes that contribute to the pathogenesis of atopic dermatitis. In
this review, we summarize the current understanding of the innate immune
functions of keratinocytes in the pathogenesis of atopic dermatitis,
with a special emphasis on skin-derived antimicrobial peptides and
atopic dermatitis-related cytokines and chemokines in keratinocytes. An
improved understanding of the innate immunity mediated by keratinocytes
can provide helpful insight into the pathophysiological processes of
atopic dermatitis and support new therapeutic efforts.14 Aug 2020Submitted to Clinical & Experimental Immunology 14 Aug 2020Submission Checks Completed
14 Aug 2020Assigned to Editor
17 Aug 2020Reviewer(s) Assigned
29 Oct 2020Review(s) Completed, Editorial Evaluation Pending
29 Oct 2020Editorial Decision: Revise Minor
25 Dec 20201st Revision Received
30 Dec 2020Reviewer(s) Assigned
04 Jan 2021Review(s) Completed, Editorial Evaluation Pending
04 Jan 2021Editorial Decision: Accept
13 May 2021Published in Clinical and Experimental Immunology volume 204 issue 3 on pages 296-309. 10.1111/cei.13575